srch

Børskommentar: Gode nyheter bør ikke komme for tidlig for Bergenbios småaksjonærer. 05.05.20 ... Bergenbio-byks etter nyhet om rask prosess i USA. 22.10.19.

Fergeselskap setter alle passasjerer på land i påvente av «stor nyhet». Britiske P&O Ferries melder torsdag at det har midlertidig stanset driften, ...

En del investorer har presset på for å komme seg ut av aksjen de siste ukene, sier Geir Linløkken i Investtech. Analytikeren advarer mot åtte aksjer på Oslo ...

Mar 17, 2022 · BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients. January 27, 2022. Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…. Read More.

Bergenbio tapte 69 millioner kroner i fjerdekvartal 2021. Legemiddel- og bioteknologi-selskapet Bergenbio tapte 69 millioner kroner i resultat før skatt i fjerdekvartal 2021. Det fremkommer av selskapets kvartalsrapport som ble offentliggjort onsdag morgen. Tapet i kvartalet er fem millioner forbedring fra samme kvartal i 2020 da underskuddet ...

Dec 16, 2021 · BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.

Kjøp BERGENBIO (BGBIO) aksjen. Hos Nordnet kan du handle fra 1 kr i kurtasje. Klikk her for å følge aksjekursen i realtid

12.07.2021 · BerGenBio med oppløftende nyheter – aksjen rett opp ... BerGenBio har presentert en kombinert analyse av data fra to fase 2-studier som har undersøkt bruken av medikamentet bemcentinib på innlagte covid-19-pasienter ved European Congress of Clinical Microbiology & Infectious Diseases.

Jan 10, 2021 · Flink forsker som også har trua på BerGenBio…. Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of ...

03.02.2022 · Men norske BerGenBio stiger kraftig etter nyheten om at en medisin de lager, er effektiv mot alvorlig covid-19. Norsk kreftmedisin mer effektiv enn ventet mot covid-19 Adressa - Nyheter 13.07.2021 04:33:08 Related

Sep 07, 2021 · BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

Bergenbio-byks etter nyhet om rask prosess i USA. Bergenbio kommer tirsdag med gode nyheter om kreftmedisinen selskapet har utviklet, bemcentinib.. Hegnar.no - 19 aug 19 kl. 07:26 Slik gikk det med Bergenbio i andre kvartal. Bergenbio presenterte tall for andre kvartal mandag..

Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors ...

Følg kursbildet, nyheter, teknisk analyse og børsmeldinger for BERGENBIO.

CisionWire - NO - Nyheter 16.02.2022 06:55:11 Related. Bergen, Norway, 16 February 2022 The Board of Directors in BerGenBio ASA (the"Company") (OSE: BGBIO) ...

Nov 17, 2021 · Bergen, Norway, 17 November 2021 - Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 9 November 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of options pursuant to the Company's share option program.

16.02.2022 · Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, taking place online ...

Legemiddelet er opprinnelig utviklet mot kreft. Coronaviruset. Flere nyheter arrow_downward. Dette skjer i dag: VG følger situasjonen i Ukraina og nyheter fra ...

Jan 10, 2021 · BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021. Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e ...

... Fotball: Live-senter · Karriere i Amedia · Kart · Korona · Lokalavisenes søknadsordning · Løssalg · Markedsplassen · Nyheter · Oddstipset · Personalia ...

16.12.2021 · BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth quarter and full year 2021. A briefing.

30.09.2021 · BERGENBIO ANNOUNCES POSTER PRESENTATION AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2021. Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce …

Mar 17, 2022 · BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

10.01.2021 · Spennende nyheter fra BerGenBio’s samarbeids-partner. Merck's Keytruda reduced risk of recurrence or death by 24% in early lung cancer patients. PUBLISHED THU, MAR 17 20222:17 PM EDTUPDATED 4 HOURS AGO Spencer Kimball @SPENCEKIMBALL